The Allen Institute in Seattle has launched the Brain Health Accelerator, a ambitious fourteen-year, $200 million project designed to map the human brain to uncover therapeutic targets for neurodegenerative diseases. Building on its successful Seattle Alzheimer's Disease Brain Cell Atlas, the institute plans to analyze postmortem tissue from thousands of donors, including both healthy individuals and those affected by Parkinson's, Huntington's, and amyotrophic lateral sclerosis (ALS). This expansion marks a shift from focusing solely on proteinopathies like amyloid and tau to mapping specific cell types and neural circuits that fail during disease onset. Led by neuroscientist Ed Lein, the initiative aims to define affected cellular structures to identify intervention points that may be relevant across multiple disorders. The project leverages advanced molecular technologies and artificial intelligence to process vast datasets generated from the brain tissue. A critical component of the accelerator involves creating maps of nonhuman primate brains to align cell types between humans, primates, and mice. This precise cross-species matching is intended to reduce risks for drug developers testing gene therapies and other treatments on specific cell types. The scale of the new effort represents a significant increase in resources, with a budget more than double that of the institute's previous Alzheimer's study. It involves collaboration with 28 institutions, including universities and disease-focused nonprofits like EverythingALS. While the National Institutes of Health supports the broader field through the Brain Research through Advancing Innovative Neurotechnologies Initiative, it is not a direct funder of this specific project. Experts in the field, such as Bradley Boeve of the Mayo Clinic and Cristina Sampaio of the CHDI Foundation, view the project as a vital step toward addressing gaps in cellular and circuit-level understanding, particularly for conditions like frontotemporal dementia. Despite the optimism, the project faces notable logistical challenges. The primary hurdle, described by Sampaio as the human factor, involves securing a consistent supply of human donor brains accompanied by detailed clinical and imaging records. Furthermore, participating institutions must adapt their protocols to preserve tissues for high-resolution analysis, such as RNA sequencing, which identifies active genes within cells. Despite these obstacles, the scientific community anticipates substantial breakthroughs. John Ngai of the NIH notes that researchers are reaching an inflection point where targeting virtually any brain cell type becomes feasible. Lein predicts that the consortium's foundational work could lead to the first human clinical trials of therapies derived from this research within five years. By providing a comprehensive atlas of brain health and disease, the Allen Institute hopes to accelerate the development of individualized treatments for a wide range of neurological conditions.